<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657748</url>
  </required_header>
  <id_info>
    <org_study_id>P070803</org_study_id>
    <nct_id>NCT00657748</nct_id>
  </id_info>
  <brief_title>Lithium and Acetate for Canavan Disease</brief_title>
  <official_title>Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Leukodystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether oral supplementation with lithium and acetate
      may improve the biological and clinical prognosis in patients with Canavan Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Canavan Disease is an autosomal recessive devastating demyelinating disease caused by a
      deficiency in Aspartoacylase (ASPA) enzyme. There is no available treatment. ASPA deficiency
      leads to:- the accumulation of high levels of N-acetylaspartate (NAA), involved in myelin
      degeneration and epilepsy;- the deficient synthesis of acetate in oligodendrocytes, that
      could impair CNS myelination.Lithium administration induces a decrease in NAA in the brain of
      the tremor rats (animal model for CD) and in one patient (JANSON, 2005). On the other hand,
      administration of acetate could improve myelination in Canavan patients.For this reason, we
      propose to combine both treatments: Lithium Gluconate and Glyceryl Triacetate (GTA). Eighteen
      patients, aged 1 to 15 years, will receive oral GTA or Lithium during 4 months, then both
      treatment in association during 6 months. Patients will be sequentially evaluated up to the
      end of the treatment and 2 months thereafter for:-tolerance of the therapy (careful
      monitoring of clinical and biological parameters).- efficacy of the therapy on clinical,
      biological and radiological parameters. Particularly, we will evaluate using MRI-spectroscopy
      and CSF samples the decrease in NAA and increase in acetate levels in the brain.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be a decrease of the NAA peak (&gt; 20%) or the appearance of an acetate peak at the end of the treatment (10 months), using spectroscopy-MRI.</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes will be assessed at 10 months (end of the treatment): -Improvement of neuromotor performances (GMFM and Mullen scales), spasticity, and neurological severity</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Improvement of epilepsy (number of seizures)</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Decrease in NAA and increase in acetate contents in fluids (CSF, plasma, urine).</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Canavan Disease</condition>
  <condition>Infantile</condition>
  <condition>Deficiency Disease</condition>
  <condition>Aspartoacylase</condition>
  <condition>Leukodystrophy, Spongiform</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)</intervention_name>
    <description>Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lithium Gluconate (drug)</other_name>
    <other_name>Glyceryl Triacetate, GTA (drug)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and biochemical diagnosis of Canavan disease

        Exclusion Criteria:

          -  Renal disease

          -  Thyroid disease

          -  Cardiac disease

          -  Impossibility to perform brain MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Aubourg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Sevin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.ela-asso.com/</url>
    <description>ELA (European Leukodystrophy Association)</description>
  </link>
  <results_reference>
    <citation>Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther. 2005 Oct;315(1):297-303. Epub 2005 Jul 7.</citation>
    <PMID>16002461</PMID>
  </results_reference>
  <results_reference>
    <citation>Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5221-6. Epub 2005 Mar 22.</citation>
    <PMID>15784740</PMID>
  </results_reference>
  <results_reference>
    <citation>Janson CG, Assadi M, Francis J, Bilaniuk L, Shera D, Leone P. Lithium citrate for Canavan disease. Pediatr Neurol. 2005 Oct;33(4):235-43.</citation>
    <PMID>16194720</PMID>
  </results_reference>
  <results_reference>
    <citation>Baslow MH, Kitada K, Suckow RF, Hungund BL, Serikawa T. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res. 2002 May;27(5):403-6.</citation>
    <PMID>12064356</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <name_title>Yannick VACHER</name_title>
    <organization>Department Clinical Research and Developpement</organization>
  </responsible_party>
  <keyword>Leukodystrophy</keyword>
  <keyword>Canavan disease,</keyword>
  <keyword>Aspartoacylase,</keyword>
  <keyword>Lithium,</keyword>
  <keyword>Glyceryl Triacetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Canavan Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Triacetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

